IMPACT HAS A SOPHISTICATED DISCOVERY ENGINE THAT HAS GENERATED AN EXTENSIVE PIPELINE OF NEW MOLECULES . the world ’ s most therapeutically meaningful and commercially successful oncology medicines .” said IMPACT CEO Sui Xiong Cai , PhD .
INDUSTRY WATCH
Impact Therapeutics enters global partnership with Eikon Therapeutics to develop and commercialize PARP1 Selective Inhibitors
Eikon Therapeutics , a biotech specialist advancing breakthrough therapeutics through the integration of engineering and science , has partnered with IMPACT Therapeutics , a biopharma company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality , to enter into a global license and collaboration agreement for PARP1 selective inhibitors – including IMP1734 anticipated to enter Phase I clinical study this year .
Under the collaboration agreement , Eikon received an exclusive license from Impact to co-develop , register , manufacture and commercialize IMP1734 and other PARP1 selective inhibitors globally , excluding Greater China ( mainland China , Hong Kong , Macau , and Taiwan ).
“ We are delighted to establish the global partnership with Eikon , whose leadership team has a welldocumented track record of developing some of
IMPACT HAS A SOPHISTICATED DISCOVERY ENGINE THAT HAS GENERATED AN EXTENSIVE PIPELINE OF NEW MOLECULES . the world ’ s most therapeutically meaningful and commercially successful oncology medicines .” said IMPACT CEO Sui Xiong Cai , PhD .
“ As a company committed to develop innovative medicines globally , based on our deep understanding of synthetic lethality , we believe this partnership will allow us to accelerate the development of our PARP1 selective inhibitor program combining Impact and Eikon ’ s scientific , clinical , regulatory expertise and financial resources .
“ We look forward to working with Eikon in bringing new cancer medicines to patients in China and across the globe .”
Roger M . Perlmutter , MD , PhD , CEO and Board Chair of Eikon Therapeutics said : “ Impact has a sophisticated discovery engine that has generated an extensive pipeline of new molecules , including the development of senaparib , a dual PARP1 / 2 inhibitor that has been recently reported to improve outcomes in patients with advanced ovarian cancer .
“ Eikon is delighted to partner with Impact scientists to help develop IMP1734 and other selective PARP1 inhibitors that exploit DNA damage response aberrations often found in tumors to selectively kill cancer cells . Eikon is confident that we can leverage our expertise , resources and proprietary technology platforms , in partnership with Impact , to bring these important new PARP1 inhibitor therapies to patients who are awaiting new and better treatment options .” p
74 INTELLIGENTCIO NORTH AMERICA www . intelligentcio . com